For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Noriaki Ishida, General Manager,
Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/
Daiichi Sankyo Launches RANMARK(R), a Treatment for Bone Complications Stemming from Multiple Myeloma and Bone Metastases from Solid Tumors
Tokyo, Japan (April 17, 2012) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched RANMARK® (Subcutaneous Injection 120 mg) (INN: Denosumab (genetic recombination); Approval to market: January 18, 2012; NHI drug price listing: April 17, 2012) in Japan as a treatment for bone complications stemming from multiple myeloma and bone metastases from solid tumors.
RANMARK® is the world’s first human monoclonal antibody to target RANK ligand. It has been shown that RANMARK® suppresses the occurrence of SRE (skeletal-related events) in patients with bone complications stemming from multiple myeloma and bone metastases from solid tumors.
Daiichi Sankyo and AstraZeneca KK (an affiliate of AstraZeneca PLC) entered into a co-promotion agreement in Japan for RANMARK on May 24, 2011.
With denosumab, Daiichi Sankyo aims to benefit patients, their families, and medical professionals by augmenting the few available therapeutic alternatives for treating bone disorders stemming from multiple myeloma and bone metastases from solid tumors with a new and effective treatment option.
RANMARK® Overview
(Date of launch: April 17, 2012)
|
Product Name
|
RANMARK® Subcutaneous Injection 120 mg
|
|
Generic Name
|
Denosumab (Genetic recombination)
|
|
Price Listing
|
RANMARK® Subcutaneous Injection 120 mg: \45,155 per vial
[NHI drug price listing: April 17, 2012]
|
|
Indication
|
Treatment for bone complications stemming from multiple myeloma and bone metastases from solid tumors
|
|
Dosage and Administration
|
Generally, the dose of 120 mg is administrated subcutaneously to adults once every four weeks.
|
|
Approval Date
|
January 18, 2012
|
|
Remarks
|
Denosumab (genetic recombination) is licensed from Amgen.
|
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimise growth opportunities across the value chain. For more information, please visit: www.daiichisankyo.com.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about Amgen’s pioneering science and vital medicines, visit www.amgen.com. Follow them on www.twitter.com/amgen.
End